Tumor News and Research

RSS

Chemical signatures in blood could help detect gallbladder cancer

Researchers at Tezpur University in Assam, India, working with scientists at the University of Illinois Urbana-Champaign, have identified distinct chemical signatures in blood that could help detect gallbladder cancer earlier.

25 Feb 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

Phase 2 clinical trial tests LMP744 for the treatment of first-time recurrent glioblastoma

Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent glioblastoma patients.

25 Feb 2026

Throwing cancer-driving proteins in the cellular trash

When cancer-driving proteins resist various treatments, Northwestern University scientists have uncovered a new solution. Don't fight them - throw them in the cellular trash.

24 Feb 2026

Assessing long-term cognitive risks in ependymoma survivors

A study led by St. Jude Children's Research Hospital assessed cognitive and communication abilities in children treated for the brain tumor ependymoma to understand the impact of treatment better. They found that radiation was a significant contributor to hearing loss, a risk directly linked to cognitive health.

23 Feb 2026

Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced cancer treatment, as the first institution in Louisiana to provide an adult patient with tumor-infiltrating lymphocytes (TIL) therapy for advanced melanoma.

23 Feb 2026

Study finds microplastics in most prostate tumors

Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, a new study finds.

23 Feb 2026

Discovery offers hope for reducing immune-related heart risks in cancer patients

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

20 Feb 2026

Optimized costimulatory domains boost tumor killing in CAR NK cells

Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, such as 2B4 and DAP12.

20 Feb 2026

Stereotactic radiation improves quality of life in patients with brain metastases

In a Phase 3 randomized trial, Mass General Brigham researchers found that stereotactic radiation targeting individual tumors led to lower symptom burden, better cognitive outcomes, and better day to day function when compared with whole brain radiation

19 Feb 2026

Remote-controlled CAR T cells offer safer cancer therapy

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers.

19 Feb 2026

Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk

An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up suggested durable immune memory with encouraging relapse-free outcomes, though controlled trials are needed to confirm clinical benefit.

19 Feb 2026

Blood test shows promise in forecasting outcomes for germ cell tumors

Can fragments of tumor DNA in the blood predict whether chemotherapy will be effective? Researchers at the Princess Máxima Center investigated this question together with experts from Italy and Slovakia.

19 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Protein made by stressed cancer cells helps tumors to evade immune attack

A protein made by stressed cancer cells helps lung and pancreatic tumors evade the immune system, a new study shows.

18 Feb 2026

Developmental ANGPTL4 deficiency protects mice from colitis and tumors

A novel study using a mouse model has found that the absence of the angiopoietin-like 4 (ANGPTL4) protein during development triggers a long-lasting reprogramming of the immune system that protects against intestinal inflammation.

18 Feb 2026

Polyploidy-induced senescence may influence aging and cancer risk

A new editorial was published in Volume 18 of Aging-US on February 8, 2026, titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?"

18 Feb 2026

Researchers discover a way to breach cancer’s impenetrable fortress

Researchers at Case Western Reserve University have discovered a way to breach one of cancer's most stubborn defenses: the impenetrable fortress that solid tumors build around themselves.

18 Feb 2026

Researchers develop new score to predict the risk of liver cancer

Researchers led by Xian-Yang Qin at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have developed a score that predicts the risk of liver cancer.

17 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026